Is Cigna Stock A Real Bargain?
Today’s big story: Could Anthropic Stock Fall 25%?
Cigna (CI) stock trades at 12.5 times earnings, against 21.5 for the median S&P 500 company. It returned 7.6% over the past year, behind the S&P 500’s 11.0%. The price appears to assume that Cigna’s thin margins stay thin. To be a bargain, Cigna needs growing cash and a margin that recovers. That has to happen while its pharmacy benefit business goes through a transition. So how much cash is Cigna producing for that price?

Cigna Is Producing More Cash Than A Year Ago
Cigna generated $8.27 billion of free cash flow over the twelve months to September 30, 2026, an increase from $7.44 billion a year earlier. At the latest closing price, that cash equals 11.0% of Cigna’s market value, while the stock carries a dividend yield of 2.2%.
Cigna’s free cash flow equals 11.0% of its market value, but it pays out only 2.2% a year in dividends. If you live off your savings, that 2.2% is the part of Cigna’s cash that reaches you. Meanwhile, the Trefis Income Solution pays a dividend yield about 3x the S&P 500’s, from 50 stocks with at least 10 straight years of dividends. See what it pays.
Most of Cigna’s sales come from Evernorth Health Services. The segment brought in $235 billion of the company’s $274 billion revenue in fiscal 2025. Within Evernorth, management said the Specialty and Care Services division grew pretax adjusted earnings 15% from a year earlier in fiscal Q3 2026.
The profit behind the P/E is a little weaker. Net income was $5.99 billion over the twelve months to September 2026, compared to $6.15 billion a year earlier. This leaves Cigna with growing cash, but earnings that have slipped slightly.
Cigna Keeps Less Of Each Sales Dollar
Over a longer stretch, Cigna’s operating margin has not recovered. It was 3.9% in the twelve months to September 2022, and 3.8% a year later. It slipped to 3.6% in the twelve months to September 2024, then to 3.0% a year after that. It stayed at 3.0% in the latest twelve months, and only two quarter ends since fiscal Q4 2018 were lower.
Sales growth has slowed too. Revenue rose 6.8% in the twelve months to September 2026, against an average of 14.9% across the three latest twelve-month periods, which include this one.
Management said on the November 5, 2026 call that its pharmacy benefit services business is in a period of transition. Its results reflect renewals of large client contracts and spending on a new model called Signature.
What Is Cigna Doing About Its Pharmacy Business?
Cigna is moving pharmacy benefit clients to Signature, which management calls a simple, fee-based offer. Cigna Healthcare’s fully insured plans, where Cigna itself pays the medical claims, adopt it on January 1, 2027. Wider adoption by clients is expected in 2028.
Management expects pharmacy benefit services income to fall by a single-digit percentage in 2027. From 2026 to 2030, it expects at least 4% compounded yearly income growth from that business, along with 2030 adjusted earnings per share of at least $45. Management also raised its full-year 2026 adjusted earnings per share outlook to at least $30.60, up from $30.45 in July.
What Are Cigna Buyers Counting On?
Cigna’s cash is growing, so the cash side of the bargain holds. Its margin has not recovered, and that is the weaker side. At this price, a buyer is betting that Cigna fixes its pharmacy benefit business, not that the market misread a sound one. If that income falls as management expects, and the margin stays near its low, the discount looks more like a fair price.
Cigna is expected to report in February 2027. Management said the fourth-quarter call will bring detailed 2027 guidance by segment.
Sizing up one company’s discount against its weak spot is one way to invest, and we are happy with the approach we use. If you have found a better one, we would like to hear it.
Found A Better Strategy? We’d Love To Learn.
Ours is the Trefis High Quality (HQ) Portfolio: 30 quality stocks in equal weight. Since its September 2020 launch it has returned more than 105%, ahead of a benchmark that combines the S&P 500, S&P MidCap and Russell 2000. If yours has done better, tell us about it. If not, come take a look.
Spot an error or want more like this? Tell us in 10 seconds.